FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience.
Journal
JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
02
2021
revised:
08
06
2021
accepted:
07
07
2021
entrez:
15
11
2021
pubmed:
16
11
2021
medline:
16
11
2021
Statut:
epublish
Résumé
Cholangiocarcinomas (CCA) are a group of heterogeneous tumors arising from the biliary epithelia. Significant sequencing efforts have provided further insights into the molecular mechanisms of this disease including fibroblast growth factor receptor ( This is a retrospective study of patients with CCA and known Our group identified 61 patients with advanced or metastatic CCA, 19 males (31%) and 42 females (69%), harboring FGFRi are well tolerated with clinical efficacy. With the recent approval of FGFRi by the US Food and Drug Administration and ongoing clinical trials for new FGFRi, understanding outcomes and toxicity associated with these medications is important for precision oncology.
Identifiants
pubmed: 34778691
doi: 10.1200/PO.21.00064
pii: PO.21.00064
pmc: PMC8575436
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P30 CA015083
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2021 by American Society of Clinical Oncology.
Déclaration de conflit d'intérêts
Nguyen H. Tran Honoraria: QED Therapeutics Consulting or Advisory Role: QED Therapeutics No other potential conflicts of interest were reported. Nguyen H. Tran Honoraria: QED Therapeutics Consulting or Advisory Role: QED Therapeutics No other potential conflicts of interest were reported.
Références
J Clin Oncol. 2018 Jan 20;36(3):276-282
pubmed: 29182496
PLoS Genet. 2014 Feb 13;10(2):e1004135
pubmed: 24550739
Biomol Ther (Seoul). 2018 Jul 1;26(4):335-342
pubmed: 29949843
BMC Ophthalmol. 2020 Jan 9;20(1):19
pubmed: 31918686
Lancet Oncol. 2020 May;21(5):671-684
pubmed: 32203698
Cancer Chemother Rep. 1966 Mar;50(3):163-70
pubmed: 5910392
Gut Liver. 2019 Jan 15;13(1):104-113
pubmed: 29938462
J Gastrointest Oncol. 2018 Dec;9(6):1063-1073
pubmed: 30603125
Clin Cancer Res. 2018 Sep 1;24(17):4154-4161
pubmed: 29848569
Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1629-37
pubmed: 21750167
Invest New Drugs. 2017 Aug;35(4):451-462
pubmed: 28070720
Crit Rev Oncol Hematol. 2020 Nov;155:103091
pubmed: 32961472
Cancer Cell. 2016 May 9;29(5):711-722
pubmed: 27165743
Curr Opin Gastroenterol. 2015 May;31(3):264-8
pubmed: 25763789
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
Ther Adv Med Oncol. 2020 Jul 23;12:1758835920940948
pubmed: 32754231
Cells. 2019 Jun 18;8(6):
pubmed: 31216761
JCO Precis Oncol. 2018 Nov;2:1-12
pubmed: 35135097
Br J Cancer. 2017 Nov 21;117(11):1592-1599
pubmed: 28972963
Cancer Treat Rev. 2019 Aug;78:1-7
pubmed: 31255945
Drugs. 2020 Jun;80(9):923-929
pubmed: 32472305
Target Oncol. 2022 Sep;17(5):517-527
pubmed: 36114955
Br J Cancer. 2019 Jan;120(2):165-171
pubmed: 30420614
Front Genet. 2012 Nov 28;3:268
pubmed: 23226157
Biol Sex Differ. 2020 Apr 15;11(1):17
pubmed: 32295632
Semin Radiat Oncol. 2003 Jul;13(3):176-81
pubmed: 12903007
Oncologist. 2021 Feb;26(2):e316-e326
pubmed: 33021006
J Hepatol. 2020 Jul;73(1):170-185
pubmed: 32171892
Future Oncol. 2020 Oct;16(30):2375-2384
pubmed: 32580579
Oncotarget. 2017 Feb 28;8(9):16052-16074
pubmed: 28030802
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404